Page last updated: 2024-08-21

pyrazines and Brain Neoplasms

pyrazines has been researched along with Brain Neoplasms in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.27)	18.2507
2000's	13 (29.55)	29.6817
2010's	26 (59.09)	24.3611
2020's	4 (9.09)	2.80

Authors

Authors	Studies
Azami Movahed, M; Bagheri, Z; Hadjighassem, M; Haghi-Aminjan, H; Pourahmad Jaktaji, R; Pourahmad, J; Rahimifard, M; Zarghi, A	1
Aasen, SN; Bjørnstad, OV; Haan, C; Herdlevær, CF; Hoang, T; Preis, J; Reigstad, A; Rigg, E; Sundstrøm, T; Thorsen, F	1
Chen, Q; Gao, W; Ge, J; Liu, B; Liu, J; Tang, D; Yang, J; Zhao, J	1
Ang, BT; Cheng, HS; Chong, YK; Law, CLD; Low, ZYJ; Marvalim, C; Tan, NS; Tang, C; Zhu, P	1
Bindra, RS; Chen, EM; Focarete, ML; Jackson, C; Jiang, Z; Josowitz, AD; Merlettini, A; Noorbakhsh, S; Quijano, AR; Saltzman, WM; Seo, YE; Sundaram, RK	1
Elmquist, WF; Gampa, G; Kim, M; Mladek, AC; Mohammad, AS; Parrish, KE; Sarkaria, JN	1
Cai, X; Chen, P; Chen, Z; Ge, J; Georgakilas, AG; Hu, H; Pan, X; Tian, S; Xia, L; Yang, Y; Yu, K; Zhang, J; Zhuang, J	1
Cao, Y; Chapman, C; Friedman, J; Hamstra, D; Hayman, J; Lao, CD; Lawrence, T; Lee, O; Normolle, DP; Redman, BG; Schipper, M; Tsien, CI; Van Poznak, C	1
Feng, J; Leng, X; Li, J; Li, W; Lian, S; Wang, C; Wang, H; Zhang, X	1
Cao, Y; Farjam, R; Feng, FY; Gomez-Hassan, D; Hayman, JA; Lawrence, TS; Tsien, CI	1
Bergqvist, M; Bergström, S; Blomquist, E; Edqvist, PH; Ekman, S; Gullbo, J; Jaiswal, A; Johansson, M; Lennartsson, J; Navani, S; Pontén, F; Sooman, L; Tsakonas, G; Wu, X	1
Eberhart, CG; Hayashi, M; Kahlert, UD; Koch, K; Maciaczyk, J; Natsumeda, M; Orr, BA; Suwala, AK	1
Allan, JM; Curtin, NJ; Edmondson, R; Elstob, CJ; Fordham, S; Herriott, A; May, FE; McCormick, A; Middleton, FK; Patterson, MJ; Pollard, JR; Wade, MA	1
Baryawno, N; Calero, R; Darabi, A; Dyberg, C; Einvik, C; Johnsen, JI; Kogner, P; Kool, M; Milosevic, J; Sandén, E; Siesjö, P; Sveinbjörnsson, B; Wickström, M	1
Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Ding, X; Gini, B; Gu, Y; Heath, JR; Herrmann, K; Hwang, K; Ikegami, S; James, CD; Johnson, D; Kim, J; Li, X; Masui, K; Matsutani, T; Mischel, PS; Shin, YS; Su, Y; Wei, W; Xue, M; Yang, H; Zhou, J	1
Carlucci, G; Carney, B; Reiner, T; Sadique, A; Tang, J; Vansteene, A	1
de Jong, S; de Vries, EG; Oldenhuis, CN; Stegehuis, JH; Walenkamp, AM	1
Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP	1
Armstrong, MB; Castle, VP; Mody, R; Opipari, AW; Schumacher, KR; Yanik, GA	1
Roesler, R; Schröder, N; Schwartsmann, G	1
Burt Nabors, L; Carson, KA; Desideri, S; Grossman, SA; Lesser, G; Mikkelsen, T; Olson, JJ; Phuphanich, S; Rosenfeld, S; Supko, JG	1
Chen, CC; D'Andrea, A; Hu, L; Kesari, S; Kung, A; Ng, K; Nitta, M	1
Beck, JF; Becker, S; Gressmann, S; Schmudde, M; Sonnemann, J; Wittig, S	1
He, Q; Lin, M; Luo, P; Shen, J; Wang, Z; Yang, B; Zhu, D	1
Breen, M; Chen, CS; Keller, ET; Kisseberth, WC; Lanigan, LG; Martin, CK; McCauley, LK; Murahari, S; Nadella, MV; Rosol, TJ; Shu, ST; Simmons, JK; Thudi, NK; Van Bokhoven, A; Werbeck, JL; Williams, C	1
Bota, DA; Gong, X; Linskey, ME; Schwartz, PH	1
Balyasnikova, IV; Ferguson, SD; Han, Y; Lesniak, MS; Liu, F	1
Arnold, LA; Atkinson, JM; Boulos, N; Carcaboso, AM; Eden, C; Ellison, DW; Féau, C; Gajjar, A; Gibson, P; Gilbertson, RJ; Guy, RK; Johnson, RA; Koul, D; Kranenburg, TA; Mohankumar, KM; Phoenix, T; Poppleton, H; Priebe, W; Shelat, AA; Stewart, CF; Tong, Y; Wright, K; Yung, WK; Zhu, L	1
Anderson, SK; Buckner, J; Friday, BB; Galanis, E; Geoffroy, F; Giannini, C; Gross, H; Jaeckle, K; Mazurczak, M; Pajon, E; Schwerkoske, J; Yu, C	1
Seol, DW	1
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE	1
Ambati, B; Chen, Z; Ge, J; Pan, X; Tian, S; Yang, Y; Yu, K; Zhang, J; Zhuang, J	1
Asklund, T; Bergenheim, T; Hedman, H; Henriksson, R; Holmlund, C; Kvarnbrink, S; Wibom, C	1
Synhaeve, NE; Tijssen, CC; van der Heul, C	1
Hatzidaki, E; Koukoulis, GK; Papandreou, CN; Stathakis, NE; Vlachostergios, PJ	1
Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK	1
Alloro, E; Brocca, MC; Coppi, MR; Mele, G; Pinna, S; Quarta, G	1
Chen, J; Pamarthy, D; Sun, Y; Tan, M; Wang, S; Wu, M; Yang, D; Zhang, H	1
Ahnert, P; Bauer, M; Ganten, TM; Haas, TL; Holland, H; Koschny, R; Krupp, W; Meixensberger, J; Sprick, MR; Sykora, J; Walczak, H	1
Hatake, K	1
Kyritsis, AP; Puduvalli, VK; Rao, JS; Tachmazoglou, F	1
Cheng, FC; Cheng, H; Chou, SC; Fu, YS; Fu, YY; Hsu, SY; Kao, LS; Lin, YY; Shih, YH; Tsai, TH; Wang, JY	1
Adjei, AA; Atadja, P; Friday, BB; Sarkaria, J; Wigle, D; Yang, L; Yu, C	1
Adachi, M; Hori, T; Kawai, K; Nakai, S; Tanaka, S	1

Reviews

2 review(s) available for pyrazines and Brain Neoplasms

Article	Year
Targeting TRAIL death receptors. Current opinion in pharmacology, 2008, Volume: 8, Issue:4 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Glioma; HLA-DR4 Antigen; HLA-DR5 Antigen; Humans; Neoplasms; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand	2008
[Breast cancer and Her-2]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2007

Article

Year

Targeting TRAIL death receptors.

Current opinion in pharmacology, 2008, Volume: 8, Issue:4

Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Glioma; HLA-DR4 Antigen; HLA-DR5 Antigen; Humans; Neoplasms; Pyrazines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand

2008

[Breast cancer and Her-2].

Nihon rinsho. Japanese journal of clinical medicine, 2007, Jun-28, Volume: 65 Suppl 6

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab

2007

Trials

5 trial(s) available for pyrazines and Brain Neoplasms

Article	Year
Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiation oncology (London, England), 2013, Aug-21, Volume: 8 Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazines	2013
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. Journal of neuro-oncology, 2010, Volume: 100, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Dose-Response Relationship, Drug; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proteasome Endopeptidase Complex; Pyrazines; Treatment Outcome	2010
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro-oncology, 2012, Volume: 14, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Brain Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Hydroxamic Acids; Male; Middle Aged; Pyrazines; Survival Analysis; Vorinostat	2012
Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatric blood & cancer, 2012, Jul-15, Volume: 59, Issue:1 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate	2012
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer investigation, 2002, Volume: 20, Issue:7-8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome	2002

Other Studies

37 other study(ies) available for pyrazines and Brain Neoplasms

Article	Year
Assessment of cytotoxic effects of new derivatives of pyrazino[1,2-a] benzimidazole on isolated human glioblastoma cells and mitochondria. Life sciences, 2021, Dec-01, Volume: 286 Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzimidazoles; Biomarkers, Tumor; Brain Neoplasms; Caspase 3; Cell Survival; Glioblastoma; HEK293 Cells; Humans; Mitochondria; Pyrazines; Spectrum Analysis; Tumor Cells, Cultured	2021
CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. PloS one, 2022, Volume: 17, Issue:9 Topics: Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Melanoma; Mutation; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazines	2022
miR‑181d promotes cell proliferation via the IGF1/PI3K/AKT axis in glioma. Molecular medicine reports, 2020, Volume: 22, Issue:5 Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Glioma; Humans; Imidazoles; Insulin-Like Growth Factor I; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Signal Transduction; Transfection; Tumor Burden; Xenograft Model Antitumor Assays	2020
Kinomic profile in patient-derived glioma cells during hypoxia reveals c-MET-PI3K dependency for adaptation. Theranostics, 2021, Volume: 11, Issue:11 Topics: Animals; Antioxidants; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Glioma; Humans; Hypoxia; Male; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrrolidinones; Quinolines; Signal Transduction; Temozolomide; Transcriptome; Triazoles	2021
Biodegradable PEG-poly(ω-pentadecalactone-co-p-dioxanone) nanoparticles for enhanced and sustained drug delivery to treat brain tumors. Biomaterials, 2018, Volume: 178 Topics: Animals; Biocompatible Materials; Brain Neoplasms; Convection; Drug Delivery Systems; Drug Liberation; Hydrodynamics; Isoxazoles; Male; Nanoparticles; Polyesters; Polyethylene Glycols; Pyrazines; Radiation-Sensitizing Agents; Rats, Inbred F344; Xenograft Model Antitumor Assays	2018
Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. The Journal of pharmacology and experimental therapeutics, 2019, Volume: 368, Issue:3 Topics: Animals; Brain; Brain Neoplasms; Cell Line, Tumor; Dogs; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 3-Ring; Humans; Madin Darby Canine Kidney Cells; Male; Melanoma; Mice; Mice, Knockout; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Pyrazines; Pyrimidines	2019
Tetramethylpyrazine (TMP) protects cerebral neurocytes and inhibits glioma by down regulating chemokine receptor CXCR4 expression. Cancer letters, 2013, Aug-19, Volume: 336, Issue:2 Topics: Animals; Apoptosis; Brain Neoplasms; Calcium; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Down-Regulation; Glioma; Hydrogen Peroxide; Neurons; Pyrazines; Rats; Receptors, CXCR4	2013
Inhibition of autophagy enhances apoptosis induced by proteasome inhibitor bortezomib in human glioblastoma U87 and U251 cells. Molecular and cellular biochemistry, 2014, Volume: 385, Issue:1-2 Topics: Adenine; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Glioblastoma; Humans; Mitochondria; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Signal Transduction; Ubiquitin-Activating Enzymes	2014
Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy. Neuro-oncology, 2014, Volume: 16, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Boronic Acids; Bortezomib; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Diffusion Magnetic Resonance Imaging; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazines; Radiation-Sensitizing Agents	2014
PTPN6 expression is epigenetically regulated and influences survival and response to chemotherapy in high-grade gliomas. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Autophagy; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrazines	2014
Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. Journal of neuropathology and experimental neurology, 2015, Volume: 74, Issue:9 Topics: Adult; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Child; Glioblastoma; Humans; Pyrazines; Pyridines; Tumor Stem Cell Assay; Wnt Signaling Pathway	2015
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget, 2015, Oct-20, Volume: 6, Issue:32 Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; CHO Cells; Computational Biology; Cricetinae; Cricetulus; Databases, Genetic; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Activated Protein Kinase; Dose-Response Relationship, Drug; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Molecular Targeted Therapy; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrazines; Signal Transduction; Sulfones; Time Factors; Transfection	2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nature communications, 2015, Nov-25, Volume: 6 Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Celecoxib; Cisplatin; Colorectal Neoplasms; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioma; Glucose-6-Phosphate Isomerase; Heterocyclic Compounds, 3-Ring; Humans; Immunoblotting; Immunohistochemistry; Irinotecan; Medulloblastoma; Mice; Neoplasm Transplantation; Neoplasms; Neuroblastoma; Pyrans; Pyrazines; Pyridines; Real-Time Polymerase Chain Reaction; Sulfones; Temozolomide; Triazoles; Tumor Suppressor Proteins; Vincristine; Wnt Proteins; Wnt Signaling Pathway	2015
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer cell, 2016, Apr-11, Volume: 29, Issue:4 Topics: Adaptation, Physiological; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Profiling; Genes, erbB-1; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Models, Biological; Molecular Targeted Therapy; Multiprotein Complexes; Mutation; Neoplasm Proteins; Nitriles; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Pyrazines; Selection, Genetic; Signal Transduction; Single-Cell Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2016
Evaluation of [ Nuclear medicine and biology, 2017, Volume: 48 Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Brain Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorine Radioisotopes; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazines; Radioactive Tracers; Radiochemistry; Sulfones; Tissue Distribution	2017
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles	2008
Bortezomib as a therapeutic candidate for neuroblastoma. Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Genes, p53; Humans; Irinotecan; Neuroblastoma; NF-kappa B; Pyrazines	2008
In reference to Fu et al. (neuro-Oncology 2008:10139-152). Neuro-oncology, 2009, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Neurons; Pyrazines; Receptors, N-Methyl-D-Aspartate	2009
A small interference RNA screen revealed proteasome inhibition as strategy for glioblastoma therapy. Clinical neurosurgery, 2009, Volume: 56 Topics: Animals; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Culture Techniques; Dacarbazine; Glioblastoma; Humans; Mice; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; RNA Interference; RNA, Small Interfering; Temozolomide; Tumor Cells, Cultured	2009
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Calreticulin; Caspase 8; Cell Line, Tumor; Child; Flow Cytometry; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrazines; Vorinostat	2010
Bortezomib induces apoptosis in human neuroblastoma CHP126 cells. Die Pharmazie, 2010, Volume: 65, Issue:3 Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Dose-Response Relationship, Drug; Enzyme Activation; Gene Expression; Humans; Indicators and Reagents; Neuroblastoma; NF-kappa B; Oncogene Protein p21(ras); Poly(ADP-ribose) Polymerases; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Thiazoles; Up-Regulation	2010
Development of a brain metastatic canine prostate cancer cell line. The Prostate, 2011, Volume: 71, Issue:12 Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Bone Neoplasms; Boronic Acids; Bortezomib; Brain Neoplasms; Carcinogenicity Tests; Carcinoma; Cell Division; Cell Line, Tumor; Dogs; Immunohistochemistry; Incidence; Injections, Subcutaneous; Keratin-18; Keratin-7; Keratin-8; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Connective Tissue; Parathyroid Hormone-Related Protein; Phenylbutyrates; Prostatic Neoplasms; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Spinal Cord Neoplasms; Subcutaneous Tissue; Transplantation, Heterologous	2011
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy. Neurology, 2011, Mar-29, Volume: 76, Issue:13 Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide	2011
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. Cancer letters, 2011, Nov-28, Volume: 310, Issue:2 Topics: Animals; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioma; HEK293 Cells; Humans; Immunohistochemistry; Jurkat Cells; Male; Mice; Mice, Nude; Neural Stem Cells; Protease Inhibitors; Pyrazines; Stem Cell Transplantation; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays	2011
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer cell, 2011, Sep-13, Volume: 20, Issue:3 Topics: Animals; Boronic Acids; Bortezomib; Brain; Brain Neoplasms; Cell Proliferation; Centrosome; Drug Screening Assays, Antitumor; Ependymoma; Fluorouracil; High-Throughput Screening Assays; Insulin; Mice; Mice, Nude; Neural Stem Cells; Pyrazines; Signal Transduction; Tumor Cells, Cultured	2011
p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochemical and biophysical research communications, 2011, Dec-09, Volume: 416, Issue:1-2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Glioma; Humans; Leupeptins; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation	2011
Tetramethylpyrazine-mediated suppression of C6 gliomas involves inhibition of chemokine receptor CXCR4 expression. Oncology reports, 2012, Volume: 28, Issue:3 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Gene Expression; Glioma; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Remission Induction; Tumor Burden; Xenograft Model Antitumor Assays	2012
Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors. Anticancer research, 2012, Volume: 32, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Neural Stem Cells; Phenylbutyrates; Pyrazines; Valproic Acid; Vorinostat	2012
Intracranial mass of multiple myeloma with good response to chemotherapy. BMJ case reports, 2012, Sep-30, Volume: 2012 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Brain Neoplasms; Dexamethasone; Drug Therapy, Combination; Humans; Magnetic Resonance Imaging; Male; Melphalan; Multiple Myeloma; Pyrazines; Treatment Outcome	2012
Bortezomib downregulates MGMT expression in T98G glioblastoma cells. Cellular and molecular neurobiology, 2013, Volume: 33, Issue:3 Topics: Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Survival; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Eukaryotic Initiation Factor-2; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; NF-kappa B; Pyrazines; Signal Transduction; Tumor Suppressor Proteins	2013
Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma. Leukemia research, 2007, Volume: 31, Issue:5 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Treatment Failure	2007
p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway. Cancer biology & therapy, 2007, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Cysteine Proteinase Inhibitors; Ellipticines; Glioblastoma; Humans; Leupeptins; Mice; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; S-Phase Kinase-Associated Proteins; Transcription, Genetic; Tumor Cells, Cultured; Ubiquitin; Ubiquitin-Protein Ligases	2007
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-01, Volume: 13, Issue:11 Topics: Adolescent; Adult; Aged; Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Female; Humans; Immunotherapy; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand	2007
Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-01, Volume: 13, Issue:21 Topics: Apoptosis; Astrocytoma; Boronic Acids; Bortezomib; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Humans; Immunotherapy; Proto-Oncogene Proteins c-bcl-2; Pyrazines; TNF-Related Apoptosis-Inducing Ligand	2007
Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: potential therapeutic application for treatment of gliomas. Neuro-oncology, 2008, Volume: 10, Issue:2 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Glioma; Glutamic Acid; Microdialysis; Nerve Degeneration; Neurons; Pyrazines; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays	2008
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-oncology, 2008, Volume: 10, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; Glioma; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mitochondria; Panobinostat; Proteasome Inhibitors; Protein Transport; Pyrazines; RNA, Small Interfering	2008
Apoptosis-inducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Neurological research, 1999, Volume: 21, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Routes; Glioma; Graft Survival; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pyrazines; Quinolines; Tumor Cells, Cultured	1999